Clinical study of Roxastat combined with levocarnitine and polysaccharide iron complex in patients with chronic renal failure hemodialysis anemia
10.13303/j.cjbt.issn.1004-549x.2021.10.012
- VernacularTitle:罗沙司他联合左卡尼汀与多糖铁复合物治疗慢性肾功能衰竭患者透析后贫血的临床研究
- Author:
Changmei GAO
1
;
Juan WANG
1
Author Information
1. Department of Pharmacy, Tianjin Occupational Diseases Precaution and Therapeutic Hospital, Tianjin 300011, China
- Publication Type:Journal Article
- Keywords:
chronic renal failure;
Roxastat;
levocarnitine;
polysaccharide iron complex
- From:
Chinese Journal of Blood Transfusion
2021;34(10):1106-1109
- CountryChina
- Language:Chinese
-
Abstract:
【Objective】 To investigate the effect and prognosis of Roxastat combined with levocarnitine and polysaccharide iron complex in patients with chronic renal failure hemodialysis anemia(CRFHA). 【Methods】 A total of 70 patients with CRFHA treated in our hospital from January 2019 to December 2020 were selected as study subjects. They were divided into control group and treatment group by simple randomizaiton grouping method. After 5 cases in each group dropped out due to transfer, COVID-19 epidemic and missed follow-up, 30 cases were left in each group.The control group was treated with Roxastat, and the treatment group with L-carnitine and polysaccharide iron complex based on Roxastat. The differences in anemia parameters, iron metabolism, dialysis-related indexes and complications between the two groups were observed and compared. 【Results】 After 3 months of treatment, Hb, RBC, Hct, TIBC, FE, and FERR in the treatment group were significantly higher than those in the control group (118.36±6.64 vs 109.34±6.25, 4.32±0.264 vs 4.03±0.32, 32.37±3.30 vs 29.85±3.24, 67.62±10.66 vs 62.78±10.32, 17.87±3.81 vs 12.51±3.82, 389.37±18.30 vs 362.85±18.04, respectively, P<0.05). No significant difference in dialysis-related indicators (serum creatinine, blood phosphorus, and blood calcium) between the two groups before and after 3 months of treatment was noticed (P>0.05). Blood creatinine of patients after 3 months of treatment was significantly higher (control group: 1 016.27±122.14 vs 1 052.27±96.23; observation group 1 014.23±121.57 vs 1 056.25±96.82, P<0.05); blood phosphorus (control group: 2.21±0.21vs 2.14±0.21; observation group: 2.23±0.30 vs 2.15±0.64) was significantly lower(P<0.05); blood calcium (control group: 2.07±0.51 vs 1.85±0.54; observation group 2.05±0.50 vs 1.87±0.52) was significantly lower (P<0.05 ). A comparison of complications between the two groups of patients after 6 months of treatment showed that the combined incidence of gastrointestinal function, increased blood pressure, and fever in the treatment group was lower than that in the control group, and the difference was statistically significant (P<0.05). 【Conclusion】 Roxastat combined with L-carnitine and polysaccharide iron complex in patients with CRFHA has definite effect, which improves dialysis-related indicators, has great advantages in optimizing anemia parameters and iron metabolism, and provides reference value for clinical treatment of CRFHA
